Clinical trials of active vaccination in metastatic melanoma patients

We have continued recruitment of patients and obtained first data in the two clinical trials of active vaccination in metastatic melanoma. Structural works that have been performed to up-grade the GMP facility for conduction of phase III clinical trials has limited the number of patients recruited. Nonetheless, we were able to complete the vaccination schedule in 4 patients and to perform additional injections in disease free patients, in patients with stable disease or with slowly progressive disease. We could not recruit new patients because the generation in GMP conditions of additional aliquots of the vaccines (i.e. the supernatant containing the infective MAGE-3 encoding viruses and the natural tumour peptides) is taking longer then predicted because of new viral controls required by the Regulatory Agency and of difficulties in purchasing clinical grade dialysis’ membranes for peptides production. As far as the planning of new protocols concerns we are waiting to know whether grant applications we applied for the specific issues will be funded.

Thus so far the 2 clinical trials are on hold until problems in GMP production of the vaccine have been solved.

• molecule type
• peptide,
• melanoma antigen MAGE-3

• cell component type
• membrane

• organism type
• Viruses,
• Homo sapiens

• experimental design type
• in vivo design experiment

created over 16 years ago (2 March 2009)    last modified over 13 years ago (10 November 2011)   [ RDF ]   [ RelFinder ]